New combo pill could slash stroke risk by crushing cholesterol

NCT ID NCT07307989

Recruiting now Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining a statin with ezetimibe (another cholesterol-lowering drug) works better than a statin alone in people who recently had a stroke. Researchers will enroll 300 adults aged 20 or older who had a stroke or TIA within the past 30 days and have high LDL cholesterol. Participants will be randomly assigned to one of two groups and followed to see if the combo helps more people reach a target LDL level below 70 mg/dL.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: statin plus ezetimibe
What this could lead to: If successful, this could show that a simple two-drug combination is more effective than a statin alone at lowering cholesterol after a stroke, potentially reducing the risk of future strokes.
What could go wrong: This is a phase 2 trial with 300 participants, so results are still early. The combination may not prove significantly better, and some patients may experience side effects like muscle pain or digestive issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia ischemic stroke transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEREMIA ISCHEMIC STROKE

Contacts and locations

Locations

Chang Gung Memorial Hospital, Chiayi Branch
RECRUITING

Pozi, 613, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.